IISER-T'Puram Scientist wins Ramanujan Fellowship

Ramesh Rasappan has to work on ‘Stereoconvergent Cross-Coupling: Asymmetric Synthesis of Boronic Esters and Silanes’ over the next five years

Published: 23rd December 2015 04:51 AM  |   Last Updated: 23rd December 2015 04:51 AM   |  A+A-

Better drugs, at lower costs, will no longer be a dream, if the research taken up by Ramesh Rasappan, an IISER-Thiruvananthapuram faculty, is successful. He has won the Ramanujan Fellowship instituted by Department of Science and Technology to work on ‘Stereoconvergent Cross-Coupling: Asymmetric Synthesis of Boronic Esters and Silanes’ for the next five years.

The Assistant Professor at School of Chemistry, IISER-Thiruvananthapuram, says, “Suppose the usual synthesis has 5-10 steps, the methodology I am trying to develop will have just one or two steps. However, it will not just be simpler or more cost-effective, but improved. For, if successful, it will help improve the purity of the drug.”

IISE.jpgTo understand asymmetric synthesis, one needs to know that most drugs are 3D molecules. Each 3D molecule will have two or more isomers, which have the same chemical composition, but different arrangement of atoms. When these are mirror images of each other, these are called enantiomers.

Ramesh explains, “Imagine you are standing in front of a mirror. You and your mirror image look similar, but is not the same, isn’t it? Likewise, a 3D molecule will have two isomers. Both will have the same composition, but different 3D orientations.”

This will lead to them having different properties. For example, a non-saccharide sweetener called Aspartame has two enantiomers, one which tastes sweet, and the other which is tasteless.

“If there are two isomers, only one would be beneficial. The other could be inactive or have side-effects. Asymmetric catalysis aims at the synthesis of a single isomer,” says Ramesh.

Though the history of asymmetric synthesis dates back to the 1800s, it would not assume significance in the pharmaceutical industry until the Thalidomide tragedy. Introduced in Germany as an over-the-counter drug in 1957, Thalidomide would be prescribed as a sedative ‘safe for everyone’ and for morning sickness in pregnant women.

But in the sixties, there were reports of around 10,000 babies born with deformities. The reason would be traced back to one of the two enantiomers of Thalidomide. After this incident, the pharmaceutical industry would investigate into methods to synthesise the beneficial isomer, rather than a mixture of isomers.

“We will not be improvising an existing methodology. It will be a completely new and simpler one,” says Ramesh.

The Fellowship is given to scientists who are doing Post-Doctoral abroad and are willing to return to India. Ramesh applied for Ramajunan Fellowship while pursuing his post-doctoral at School of Chemistry, Bristol, England.

He will receive Rs 7 lakh per year for the research.

Ramesh says, “Much has changed in India. Just ten years ago, the lab facilities for advanced research were poor in the country. But now, it is different, especially IISERs. Compared to many other national science and technology institutions, they have good funding for research,” he says.

He is also happy that he is not too far from Namakkal, his home town in Tamil Nadu.

Stay up to date on all the latest Thiruvananthapuram news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.